Author

Helen Tyrrell 1

1 Roche Products L

ETROLIZUMAB INDUCTION THERAPY IMPROVED ENDOSCOPIC SCORE, PATIENT-REPORTED OUTCOMES, AND INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE TO SEVERE UC WHO HAD FAILED TNF ANTAGONIST THERAPY: RESULTS FROM THE HICKORY OPEN-LABEL INDUCTION (OLI) TRIAL

Laurent Peyrin-Biroulet, David T. Rubin, Brian G. Feagan, Young S. Oh, Udaysankar Arulmani, Helen Tyrrell, Romeo Maciuca, Sarah Williams, Swati Tole, James Thommes

ETROLIZUMAB VERSUS INFLIXIMAB FOR TREATING PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 GARDENIA STUDY

Silvio Danese, Jean-Frederic Colombel, Milan Lukas, Javier Gisbert, Geert R. D'Haens, Bu Hayee, Remo Pannacione, Hyun-Soo Kim, Walter Reinisch, Helen Tyrrell, Young Oh, Swati Tole, Akiko Chai, Kirsten Chamberlain-James, Meina Tao Tang, Stefan Schreiber

ETROLIZUMAB VERSUS PLACEBO IN TUMOR NECROSIS FACTOR ANTAGONIST NAIVE PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM THE RANDOMIZED PHASE 3 LAUREL TRIAL

Severine Vermeire, Peter L Lakatos, Timothy Ritter, Stephen B Hanauer, Brian Bressler, Reena Khanna, Kim Isaacs, Saumin Shah, Alysha Khavarian Kadva, Helen Tyrrell, Young Oh, Swati Tole, Akiko Chai, Jennifer Pulley, Wenhui Zhang, Brian G. Feagan

Item 1 - 3 / 3
1